Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Circulation

• Publication date

  2007-02-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.106.625574PMID 17261662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.

  2006cited by this paper
• Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.

  2006cited by this paper
• Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

  2006cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• [Management of chronic heart failure].

  2005cited by this paper
• A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics

  2005cited by this paper
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

  2004cited by this paper
• Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

  2004cited by this paper
• Beneficial effects of statins in patients with non-ischemic heart failure

  2004cited by this paper
• Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure

  2004cited by this paper
• Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure

  2003cited by this paper
• Should patients with chronic heart failure be treated with "statins"?

  2003cited by this paper
• Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

  2002cited by this paper
• Statins and chronic heart failure: do we need a large-scale outcome trial?

  2002cited by this paper
• Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure.

  2002cited by this paper
• Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor

  2001cited by this paper
• Pravastatin down-regulates inflammatory mediators in human monocytes in vitro.

  2000cited by this paper
• Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia.

  2000cited by this paper
• Overview of the relationship between ischemia and congestive heart failure

  2000cited by this paper
• Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.

  1999cited by this paper
• Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein

  1999cited by this paper
• Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

  1999cited by this paper
• Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure.

  1999cited by this paper
• The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment.

  1999cited by this paper
• Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

  1998cited by this paper
• Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial

  1998cited by this paper
• The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.

  1997cited by this paper
• Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.

  1997cited by this paper
• The management of chronic heart failure.

  1996cited by this paper
• Statins do more than just lower cholesterol.

  1996cited by this paper
• Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.

  1995cited by this paper
• Early versus late congestive heart failure after initially uncomplicated anterior wall acute myocardial infarction.

  1995cited by this paper
• Neurohormonal interactions and adaptations in congestive heart failure.

  1988cited by this paper

• A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure

  2025cites this paper
• The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future.

  2024cites this paper
• Inflammation as a therapeutic target in heart failure with preserved ejection fraction

  2023cites this paper
• Riluzole is associated with reduced risk of heart failure

  2023cites this paper
• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

  2023cites this paper
• QSPR Analysis of Some Important Drugs Used in Heart Attack Treatment via Degree-Based Topological Indices and Regression Models

  2023cites this paper
• Preventing new-onset heart failure: Intervening at stage A

  2023cites this paper
• Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?

  2022cites this paper
• Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

  2021cites this paper
• HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction

  2021cites this paper
• Stage A Heart Failure: Modern Strategies for an Effective Prevention.

  2021cites this paper
• Hydrophilic or Lipophilic Statins?

  2021cites this paper
• Inflammation in Heart Failure: JACC State-of-the-Art Review.

  2020cites this paper
• Heart Failure as a Consequence of Ischemic Heart Disease

  2020cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

  2019cites this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cites this paper
• The Relationship Between Statin Action On Thyroid Autoimmunity And Vitamin D Status: A Pilot Study.

  2018cites this paper
• Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications

  2018cites this paper
• Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial

  2017cites this paper
• 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document

  2017cites this paper
• Statine bei Herzinsuffizienz

  2017cites this paper
• Heart failure

  2017cites this paper
• Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis

  2017influential citation
• 4 Diastolic Heart Failure

  2017cites this paper
• Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias

  2017cites this paper
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• Different cardiometabolic effects of atorvastatin in men with normal vitamin D status and vitamin D insufficiency

  2016cites this paper
• Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3.

  2016cites this paper
• Lipids, Statins and Heart Failure: An Update.

  2016cites this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

  2016cites this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cites this paper
• Basic Research MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction

  2015cites this paper
• Selenium and coenzyme Q10 interrelationship in cardiovascular diseases--A clinician's point of view.

  2015cites this paper
• Lipophylic Statins in Heart Failure.

  2015cites this paper
• Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study

  2015cites this paper
• Evaluation of Short Term Effect of Atorvastatin on Myocardial Performance and Its Pleiotropic Effects on Ischemic Heart Failure

  2015cites this paper
• Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry.

  2015cites this paper
• Different Effects of Atorvastatin on Metabolic and Cardiovascular Risk Factors in Hypercholesterolemic Women with Normal Thyroid Function and Subclinical Hypothyroidism

  2015cites this paper
• MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.

  2015cites this paper
• Estatinas lipófilas en la insuficiencia cardiaca

  2015cites this paper
• Development of Therapeutic Strategy to Restore Coronary Microcirculation and VEGF Signaling Cascade in Diabetes: A Novel Approach to Prevent Cardiac Complication in Diabetes

  2014cites this paper
• Treating Heart Failure With Preserved Ejection Fraction

  2014cites this paper
• MicroRNA-208a Increases Myocardial Fibrosis via Endoglin in Volume Overloading Heart

  2014cites this paper
• Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients

  2014cites this paper
• Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).

  2014cites this paper
• Appropriate candidates for statin use in heart failure

  2014cites this paper
• Lipid-modifying treatments for heart failure: is their use justified?

  2014cites this paper
• Failure: Is Their Use Justified?

  2014cites this paper
• Pleiotropic effects of statin in therapy in heart failure: a review.

  2014cites this paper
• Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?

  2014cites this paper
• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

  2014cites this paper
• Amelioration of cisplatin-induced nephrotoxicity by statins

  2013cites this paper
• Stiff Heart and Stiff Arteries. Could We Soften Both

  2013cites this paper
• Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: results from The Daunia Heart Failure Registry

  2013cites this paper
• Srce i krvni Sudovi

  2013cites this paper
• Safety of statins

  2013cites this paper
• Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

  2013cites this paper
• Statin Wars: The Heavyweight Match-Atorvastatin versus Rosuvastatin for the Treatment of Atherosclerosis, Heart Failure, and Chronic Kidney Disease

  2013cites this paper
• Statins in heart failure: do we need another trial?

  2013cites this paper
• Low-density lipoprotein levels in patients with acute heart failure.

  2013cites this paper
• Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.

  2013cites this paper
• Modeling hard clinical end-point data in economic analyses

  2013cites this paper
• Evidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination Survey.

  2012cites this paper
• mmediate administration of atorvastatin decreased he serum MMP-2 level and improved the prognosis or acute heart failure

  2012cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• Diastolic Heart Failure

  2012cites this paper
• Therapeutic Class Overview HMG CoA Reductase Inhibitors

  2012cites this paper
• Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).

  2012influential citation
• Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure.

  2012cites this paper
• Statins in heart failure: the paradox between large randomized clinical trials and real life.

  2012cites this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cites this paper
• Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?

  2011cites this paper
• Statins and myocardial remodelling: cell and molecular pathways

  2011cites this paper
• Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry

  2011cites this paper
• Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy.

  2011cites this paper
• When are pro-inflammatory cytokines SAFE in heart failure?

  2011cites this paper
• Statins in non‐ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding

  2011cites this paper
• What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?

  2011cites this paper
• Residual cardiac risk reduction beyond lipid lowering.

  2011cites this paper
• Unending debate: statin dilemma in the management of heart failure.

  2011cites this paper
• Metabolic Syndrome and Heart Failure—The Risk, Paradox, and Treatment

  2011cites this paper
• Residual Cardiac Risk Reduction Beyond Lipid

  2011cites this paper
• Cardiorenal-anemia syndrome - definition, epidemiology and management: The Cardiologist's view

  2011cites this paper
• Chapter 11 – Activation of Inflammatory Mediators in Heart Failure

  2011cites this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cites this paper
• ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cites this paper
• ESC / EAS Guidelines for the management of dyslipidaemias

  2011cites this paper
• [ESC/EAS Guidelines for the management of dyslipidaemias].

  2011cites this paper
• Pleiotropic Effects of Statins

  2010cites this paper
• From the Editor New Clinical Powers, New Ethical Questions 775

  2010cites this paper
• European workshop in periodontal health and cardiovascular disease consensus document

  2010cites this paper
• Medical Therapy for Heart Failure

  2010cites this paper
• Statins and Heart Failure - Reply

  2010cites this paper
• Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure.

  2010cites this paper
• "For me there is no substitute"-authenticity, uniqueness, and the lessons of lipitor.

  2010cites this paper
• Lipid-lowering drugs and heart failure: where do we go after the statin trials?

  2010cites this paper
• Statins and heart failure.

  2010cites this paper
• Statin treatment for patients with heart failure

  2010cites this paper
• Pleiotropic Effects of Statins

  2010cites this paper